Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.

AstraZeneca has revealed phase 2b results with its oral PCSK9 inhibitor AZD0780, including a more than 50% reduction in LDL-cholesterol when added to standard therapy, as it tries to narrow a lead ...

AstraZeneca has joined the ranks of pharma companies seeking to bring drugs targeting lipoprotein(a) to market, paying $100 million upfront for rights to a drug developed by CSPC Pharmaceutical. The ...

The dyslipidemia market is expected to witness significant growth, driven by an aging population, increasing awareness of cardiovascular health, and the introduction of novel therapies such as AZD0780 ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Study Overview: AstraZeneca, in ...

AstraZeneca ((AZN)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to ...

Merck MRK is thriving on new products and pipeline candidates to drive its long-term growth. The company has built a substantial portfolio of new pipeline candidates and has made meaningful regulatory ...

MSD Ireland's site in Carlow. MSD employs more than 3,000 people in Cork, Dublin, Carlow, Meath, Tipperary, and Louth. MSD's oral drug met the main goal of reducing bad cholesterol in a late-stage ...

Under terms of the deal, CSPC will receive $110 million upfront, with potential milestone payments reaching up to $5.22 billion, in addition to single-digit royalties. AI-Powered Collaboration: ...

June 9 (Reuters) - Merck's (MRK.N), opens new tab oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond ...

(Reuters) -Merck's oral cholesterol pill succeeded in two late-stage studies, marking a win for the drugmaker as it focuses on the development of growth drivers beyond its cancer drugs and vaccines.